IceCure Medical Ltd. reported preliminary unaudited sales of $525,000 for Q2 2025 and $1.25 million for the first half of 2025, citing adverse effects from delayed shipments and a loss of $100,000 in revenue due to a distribution agreement, leading to expectations of higher net loss compared to the same period last year. This filing also references a rights offering announcement dated July 10, 2025.